Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Treatment of WEHI 231 or CH33 immature B lymphocytes with antisera against their expressed surface IgM (anti-
IgM), which serves as B Cell Receptor (BCR), induces G1/S phase growth arrest followed by apoptosis. These cell
lines have served as models for the study of tolerance via clonal deletion, and have provided important insights into
mechanisms leading to death of B cell neoplasias. Work by several laboratories has demonstrated the drop in c-Myc
oncogene expression resulting from BCR engagement promotes cell death. In this application, studies are focused on
elucidation of how members of the c-Myc/Max/Mad network exert their affects. Work by the PI's laboratory has
implicated both initiator (Inr) and E-box regulatory pathways in apoptosis mediated by anti-IgM treatment.
Specifically, it has been shown: 1) the induction in p27 ripl levels is due to both transcriptional and post-
transcriptional mechanisms; 2) c-Myc can repress transcription ef the p27 gene; 3) c-Myc can bind to the Inr element
of the p27 gene in the presence of Max; 4) Forkhead FKHRL1 factor is induced following anti-IgM treatment; 5)
transactivation of p27 promoter by FKHRL1 can be repressed by c-Myc; 6) the drop in c-Myc is followed by an
increase in expression of Max negative regulatory binding partner Mad1 and a decline in E-box gene expression. 7)
inhibition of ornithine decarboxylase (ODC) promotes apoptosis. These findings lead to the hypothesis that the drop
in c-Myc following BCR engagement promotes cell death via two pathways: release of repression of Inr-mediated
transcription and induction of repression of E-box-mediated gone expression. Experiments are proposed to: Aim 1)
Elucidate the mechanisms leading to increased p27 expression. Studies will be performed on the transcriptional
activation by Forkhead proteins, the mechanism of repression by c-Myc, the involvement of Max binding partners,
post-transcriptional control of p27, and identification of other Inr-containing genes de-repressed upon the drop in c-
Myc. Findings on the mechanism of regulation will be extended to Jurkat T, Hs578T breast cancer, and PC12
ipheochromocytoma tumor cell lines. Aim 2) Elucidate the role of induction of Max negative regulatory partners in
repression of E-box gene transcription. Studies will be performed to characterize the changes in Max binding partner
expression, and their involvement in repression of E-box regulated gene expression and the role of ODC in cell
death. These findings will enhance our understanding of the mechanism of action of the c-Myc/Max/Mad network in
signaling pathways that control expression of genes promoting apoptosis of tumor cells.
PERFORMANCESITE(S) (organization,city, state)
Boston University School of Medicine
715 Albany Street, K-624
Boston MA 02118
KEY PERSONNEL.See instructions. Use continuationpagesas neededto providethe requiredinformationinthe format shownbelow.
Startwith PrincipalInvestigator.List all other key personnelinalphabeticalorder,last namefirst.
Name Organization Roleon Project
Sonenshein, Gall E. Boston University Medical School PI
Petrovas, Constantinos Boston University Medical School Res. Associate
Jeay, Sebastien Boston University Medical School Res. Associate
DisclosurePermissionStatemenL Applicableto SBIFL/STTROnly. See instructions. [] Yes [] No
¿ PHS 398(Rev.05/01) Page2 FormPage2 ¿
¿ Principal Investigator/Program Director (Last, first, middle):
The name of the principal investigatodprogram director must be provided at the top of each printed page and each continuation page.
RESEARCH GRANT
TABLE OF CONTENTS
Page Numbers
Face Page .................................................................................................................................................. 1
Description,
No Sub Projects information available for 5R01CA036355-22
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA036355-22
Patents
No Patents information available for 5R01CA036355-22
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA036355-22
Clinical Studies
No Clinical Studies information available for 5R01CA036355-22
News and More
Related News Releases
No news release information available for 5R01CA036355-22
History
No Historical information available for 5R01CA036355-22
Similar Projects
No Similar Projects information available for 5R01CA036355-22